Opinions of the Nomination Committee of the Second Board of Directors of Shanghai Ailes Pharmaceutical Technology Co., Ltd. on the qualifications of the candidates for the position of directors of the Company’s third Board of Directors

Shanghai Ailes Pharmaceutical Technology Co., Ltd.

Nomination Committee of the Second Board of Directors

Review Opinions on the Qualifications of Director Candidates for the Company’s Third Board of Directors

The Nomination Committee of the second board of directors of Shanghai Ailes Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the "Company") reviewed the qualifications of the non-independent director candidates and independent director candidates of the company's third board of directors and issued the following review opinions:

1. The nomination of non-independent directors and independent director candidates for the third session of the Board of Directors has been approved by the nominees themselves, and the nomination procedure complies with the relevant provisions of laws, regulations and the Articles of Association.

2. Mr. Du Jinhao, Ms. Qi Ju, Mr. Hu Jie, Mr. Xu Feng and Mr. Xu Cong, the non-independent director candidates nominated for the third session of the Board of Directors, are qualified to serve as directors of listed companies. There are no circumstances found that prohibit them from serving as directors according to the "Company Law" and other laws and regulations, and no existence has been found. In the case where the China Securities Regulatory Commission has taken market ban measures from serving as directors of listed companies and the period has not yet expired, no circumstances have been found that have been publicly determined by the stock exchange to be unsuitable to serve as directors of listed companies and the period has not yet expired, and there are no bad records such as major breach of trust.

3. Ms. Zhu Chafen, Mr. Li Hanjie, and Mr. Li Chengzhang, the independent director candidates for the third session of the Board of Directors nominated this time, have passed the Shanghai Stock Exchange Independent Director Duty Performance Platform and are qualified to serve as directors of listed companies. There are no circumstances found that prohibit them from serving as directors according to the "Company Law" and other laws and regulations, and no "Independent Director Management Office of Listed Companies" has been found. Law and other laws and regulations such as the Law of the People's Republic of China and other laws and regulations prohibiting the company from serving as an independent director. It has not been found that the China Securities Regulatory Commission has taken measures to prohibit market entry from serving as a director of a listed company and the period has not yet expired. It has not been found that there is a situation that has been publicly determined by the stock exchange to be unsuitable to serve as a director of a listed company and the period has not expired. There is no bad record such as major breach of trust.

In summary, we unanimously agree to nominate Mr. Du Jinhao, Ms. Qi Ju, Mr. Hu Jie, Mr. Xu Feng and Mr. Xu Cong as non-independent director candidates for the company’s third session of the Board of Directors; agree to nominate Ms. Zhu Chafen, Mr. Li Hanjie and Mr. Li Chengzhang as candidates for the company’s third session of Board of Directors as independent directors, and agree to submit relevant proposals to the company’s board of directors for review.

上海艾力斯医药科技股份有限公司第二届董事会提名委员会

October 27, 2025